A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.

被引：0
|
作者：
Shan, Yan-Shen
Li, Chung-Pin
Khan, Gazala
Lee, Woo Jin
Choi, Hye Jin
Chang, Heung-Moon
Lee, Moon Hee
Wallmark, John M.
Chen, Pei-Ni
机构：
[1] NCKU & NCKUH, Coll Med, Tainan, Taiwan
[2] Taipei Vet Gen Hosp, Dept Med, Div Gastroenterol, Taipei, Taiwan
[3] Henry Ford Hlth Syst, Detroit, MI USA
[4] Natl Canc Ctr, Res Inst & Hosp, Goyang, South Korea
[5] Yonsei Univ Hlth Syst, Severance Hosp, Seoul, South Korea
[6] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[7] Inha Univ, Dept Internal Med, Coll Med, Incheon, South Korea
[8] Associates Oncol Hematol PC, Rockville, MD USA
[9] Golden Biotechnol Corp, New Taipei City, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-492-199-2823; 298-145-222-184-1022-9122; 283-2494; 261-492-2769; 298-145-222-184-1022-9124; 298-145-222-184-1022-8913; 283-237-267; 4; 3; 2; 219; 3618; 176; 12; 6; 1;
D O I：
10.1200/JCO.2024.42.3_suppl.648
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：648 / 648
页数：1
相关论文
共 50 条
  • [31] Phase I trial of enzalutamide in combination with gemcitabine and nab-paclitaxel in the management of advanced pancreatic cancer
    Kommalapati, A.
    Kim, R.
    Harsha, T. Sri
    Bertels, B.
    Wapinsky, G.
    Burke, N.
    Neuger, A.
    Springett, G.
    Almhanna, K.
    Mahipal, A.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E135 - E135
  • [32] Phase 1b study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer.
    Perez, Kimberly
    Rubinson, Douglas Adam
    Cleary, James M.
    Meyerhardt, Jeffrey A.
    Patel, Anuj K.
    Abrams, Thomas Adam
    Rahma, Osama E.
    Raghavan, Srivatsan
    Aguirre, Andrew
    Needle, Michael N.
    Das, Koushik
    Pitarresi, Jason
    Bakir, Basil
    Rustgi, Anil K.
    Wolpin, Brian M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer
    Hu, Zishuo Ian
    Bendell, Johanna C.
    Bullock, Andrea
    LoConte, Noelle K.
    Hatoum, Hassan
    Ritch, Paul
    Hool, Hugo
    Leach, Joseph W.
    Sanchez, James
    Sohal, Davendra P. S.
    Strickler, John
    Patel, Ravindranath
    Wang-Gillam, Andrea
    Firdaus, Irfan
    Yu, Kenneth H.
    Kapoun, Ann M.
    Holmgren, Eric
    Zhou, Lei
    Dupont, Jakob
    Picozzi, Vincent
    Sahai, Vaibhav
    O'Reilly, Eileen M.
    CANCER MEDICINE, 2019, 8 (11): : 5148 - 5157
  • [34] Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Glen J. Weiss
    Lisa Blaydorn
    Julia Beck
    Kirsten Bornemann-Kolatzki
    Howard Urnovitz
    Ekkhard Schütz
    Vivek Khemka
    Investigational New Drugs, 2019, 37 : 797 - 797
  • [35] Clinical and translational results of a phase I study, tocilizumab plus gemcitabine/nab-paclitaxel in patient with gemcitabine/nab-paclitaxel-refractory metastatic pancreatic cancer
    Mitsunaga, Shuichi
    Ikeda, Masafumi
    Aoki, Kazunori
    Yamaguchi, Kyoko
    Sawada, Noriaki
    Fujii, Etsuko
    Nishidate, Masanobu
    Fujitomo, Takashi
    Mizuno, Hideaki
    Kayukawa, Yoko
    Kato, Atsuhiko
    Makikawa, Mayu
    Imaoka, Hiroshi
    Sasaki, Mitsuhito
    Watanabe, Kazuo
    Tsunoda, Hiroyuki
    Terao, Kimio
    Ochiai, Atsushi
    CANCER RESEARCH, 2022, 82 (12)
  • [36] A PHASE I/II TRIAL OF WEEKLY NAB-PACLITAXEL (nab-P) plus GEMCITABINE(G) WITH METASTATIC PANCREATIC CANCER(MPC)
    Ikeda, Masafumi
    Ueno, Hideki
    Ueno, Makoto
    Mizuno, Nobumasa
    Ioka, Tatsuya
    Omuro, Yasushi
    Nakajima, Takako
    Furuse, Junji
    ANNALS OF ONCOLOGY, 2014, 25
  • [37] A phase I study of nab-paclitaxel (A), gemcitabine (GEM), and capecitabine (X) in patients with metastatic pancreatic adenocarcinoma (MPA)
    Thach-Giao Truong
    Tempero, Margaret A.
    Kantoff, Emily
    Jones, Kimberly
    Dito, Elizabeth
    Ong, Anna
    Ko, Andrew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer.
    Yamada, Suguru
    Fujii, Tsutomu
    Takano, Nao
    Takami, Hideki
    Suenaga, Masaya
    Niwa, Yukiko
    Hayashi, Masamichi
    Iwata, Naoki
    Kanda, Mitsuro
    Kobayashi, Daisuke
    Tanaka, Chie
    Nakayama, Goro
    Sugimoto, Hiroyuki
    Koike, Masahiko
    Fujiwara, Michitaka
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [39] A cost-utility analysis of gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer.
    Ko, Yoo-Joung
    Tam, Vincent Channing
    Mittmann, Nicole
    Pasteka, Mark
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] A phase Ib extension study of cancer sternness inhibitor BB608 (napabucasin) in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic cancer.
    El-Rayes, Bassel F.
    Shanda, Safi
    Starodub, Alexander
    O'Neil, Bert H.
    Hanna, Wahid Tewfik
    Shaib, Walid Labib
    Oh, Cindy
    Li, Wei
    Li, Youzhi
    Borodyansky, Laura
    Li, Chiang
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345